Carl Firth

ASLAN Pharmaceuticals Pte Ltd. develops novel medicines for global markets. It licenses preclinical and early clinical compounds from global pharmaceutical companies, focusing on oncology, respiratory and inflammation diseases and uses the high quality and efficient development resources available across Asia to progress the drugs through clinical development. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Exploit Technologies Pte Ltd. operates as intellectual property portfolio company. It is a technology company which transfer arm of the Agency for Science, Technology and Research. Exploit Technologies and is headquartered in Singapore.

Part of Aslan Pharmaceuticals Ltd., Aslan Pharmaceuticals Taiwan Ltd. develops novel medicines. The company is based in Taipei, Taiwan and was founded in 2014.

Part of Aslan Pharmaceuticals Ltd., Aslan Pharmaceuticals Hong Kong Ltd. is a pharmaceutical manufacturing company. The company is based in Hong Kong, Hong Kong.

Liberty Park Music Pte Ltd. offers online music lessons for various instruments such as piano, guitar, and drums. The private company is based in Singapore, Singapore. The Singaporean company's beginner to advanced lessons are taught through over 100 easy and fun videos, allowing students to learn at their own pace. The company was founded by Carl Aslan Jason Morton Firth and Brandon Wei, with Brandon Wei serving as the CEO since incorporation.

Dotbio Pte Ltd. was founded in 2017 and is based in Singapore, Singapore. The Singaporean company takes an innovative therapeutic approach towards the ideal treatment by rapidly prototyping multi-functional antibodies to identify molecules with synergistic activity combinations, optimal architectures, and unique mechanisms of action. Dotbio's approach involves the use of its modular dotbody technology platform, its cofi and hot-cofi stabilization technologies, high-throughput miniaturized assays, and data analytics to generate unique therapeutic molecules that target both extracellular and intracellular disease drivers. Dotbio has a pipeline of such molecules.